» Articles » PMID: 12200040

Senescence and Epigenetic Dysregulation in Cancer

Overview
Publisher Elsevier
Date 2002 Aug 30
PMID 12200040
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Mammalian cells have a finite proliferative lifespan, at the end of which they are unable to enter S phase in response to mitogenic stimuli. They undergo morphological changes and synthesize an altered repertoire of cell type-specific proteins. This non-proliferative state is termed replicative senescence and is regarded as a major tumor suppressor mechanism. The ability to overcome senescence and obtain a limitless replicative potential is called immortalization, and considered to be one of the prerequisites of cancer formation. While senescence mainly represents a genetically governed process, epigenetic changes in cancer have received increasing attention as an alternative mechanism for mediating gene expression changes in transformed cells. DNA methylation of promoter-containing CpG islands has emerged as an epigenetic mechanism of silencing tumor suppressor genes. New insights are being gained into the mechanisms causing aberrant methylation in cancer and evidence suggests that aging is accompanied by accumulation of cells with aberrant CpG island methylation. Aberrant methylation may contribute to many of the physiological and pathological changes associated with aging including tumor development. Finally, we describe how genes involved in promoting longevity might inhibit pathways promoting tumorigenesis.

Citing Articles

Alternative Promoters of () Gene in Human Carcinoma Cell Lines Are Regulated by Differential Methylation of CpG Dinucleotides.

Zhawar V, Kandpal R, Athwal R Genes (Basel). 2022; 13(3).

PMID: 35328043 PMC: 8954616. DOI: 10.3390/genes13030490.


Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma.

Sanaei M, Kavoosi F Iran J Pharm Res. 2021; 20(3):324-336.

PMID: 34903992 PMC: 8653641. DOI: 10.22037/ijpr.2021.115105.15197.


Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy.

Yang T, Yang Y, Wang Y Clin Epigenetics. 2021; 13(1):113.

PMID: 34001246 PMC: 8130364. DOI: 10.1186/s13148-021-01098-2.


E2F1 mediates the downregulation of POLD1 in replicative senescence.

Gao S, Song Q, Liu J, Zhang X, Ji X, Wang P Cell Mol Life Sci. 2019; 76(14):2833-2850.

PMID: 30895337 PMC: 6588650. DOI: 10.1007/s00018-019-03070-z.


Immortalization of Primary Keratinocytes and Its Application to Skin Research.

Choi M, Lee C Biomol Ther (Seoul). 2015; 23(5):391-9.

PMID: 26336577 PMC: 4556197. DOI: 10.4062/biomolther.2015.038.